Automated insulin delivery during the first 6 months postpartum (AiDAPT): a prespecified extension study [0.03%]
产后前六个月的自动化胰岛素输送（AiDAPT）：一项预设扩展研究
Tara T M Lee,Corinne Collett,Simon Bergford et al.
Tara T M Lee et al.
Background: Clinical guidelines in the UK and elsewhere do not specifically address hybrid closed loop (HCL) use in the postpartum period when the demands of caring for a newborn are paramount. Our aim was to evaluate the...
Robert A Hegele
Robert A Hegele
Laura Abaandou,Raisa Ghosh,Joanna Klubo-Gwiezdzinska
Laura Abaandou
The hypothalamic-pituitary-thyroid axis plays a crucial role in the pathogenesis, diagnosis, risk stratification, effectiveness of radioiodine therapy, and treatment response evaluation in epithelial thyroid cancer. Supraphysiological doses...
Estimating direct tissue effects versus weight loss effects of incretin-based drugs for obesity on various chronic conditions [0.03%]
基于肠降糖激素的药物对肥胖的各种慢性疾病直接组织作用与减重效果的评估
Naveed Sattar,Matthew M Y Lee
Naveed Sattar
The extent to which newer, incretin-based drugs for obesity improve disease outcomes via weight loss versus the direct effects of these drugs is the subject of intense interest. Although reductions in major adverse cardiovascular events app...
Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial [0.03%]
用于治疗PCSK9抑制的纯合子型家族性高胆固醇血症的莱罗达西班和依洛尤单抗：一项随机、开放标签、交叉对照非劣效性III期临床试验（LIBerate-HoFH）
Frederick J Raal,Vimal Mehta,Meral Kayikcioglu et al.
Frederick J Raal et al.
Background: Lerodalcibep, a small binding anti-PCSK9 protein (adnectin), showed effective LDL cholesterol reduction in heterozygous familial hypercholesterolaemia. We aimed to assess the safety and efficacy of lerodalcibe...
John W Ostrominski,Vanita R Aroda
John W Ostrominski
Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial [0.03%]
在不同基线HbA1c水平下的肥胖相关射血分数保留型心力衰竭和2型糖尿病患者中semaglutide的心衰和代谢结局分析（STEP-HFpEF DM）：一项随机、双盲、安慰剂对照试验的预先指定分析
Melanie J Davies,Peter van der Meer,Subodh Verma et al.
Melanie J Davies et al.
Background: About half of patients with heart failure with mildly reduced or preserved ejection fraction (HFpEF) have type 2 diabetes. In the STEP-HFpEF DM trial of adults with obesity-related HFpEF and type 2 diabetes, s...
The Lancet Diabetes Endocrinology
The Lancet Diabetes Endocrinology
Francesco Rubino,David E Cummings,Robert H Eckel et al.
Francesco Rubino et al.
Outcomes after medical treatment for primary aldosteronism: an international consensus and analysis of treatment response in an international cohort [0.03%]
原发性醛固酮增多症的医学治疗效果：国际共识及一项国际队列研究的疗效分析
Jun Yang,Jacopo Burrello,Jessica Goi et al.
Jun Yang et al.
Background: Primary aldosteronism can be treated medically but there is no standardised method to evaluate treatment outcomes. We aimed to develop criteria for assessing the outcomes of targeted medical treatment of prima...